Menopause in India: Navigating Symptoms, Hormones, and Long-Term Health

Menopause is the most significant hormonal transition in a woman's adult life after puberty. And yet in India, it is one of the most under-discussed and undertreated — often dismissed as a "natural" process that women should simply endure. The consequence of this dismissal is that millions of Indian women suffer through years of symptoms that are genuinely treatable, and face the long-term health consequences of oestrogen deficiency — bone loss, cardiovascular risk, genitourinary deterioration — that active management could meaningfully reduce.

This guide provides a comprehensive overview of menopause in the Indian context: when it occurs, what it causes, what the evidence says about treatment, and what long-term health management should look like.

Defining Menopause and Perimenopause

Menopause is clinically defined as the permanent cessation of menstruation, confirmed after 12 consecutive months without a period, resulting from loss of ovarian follicular activity. In India, the average age of menopause is approximately 46 to 48 years — notably earlier than the global average of 51. Premature menopause (before 40) — premature ovarian insufficiency (POI) — affects approximately 1% of women.

Perimenopause — the transition phase leading up to menopause — can begin 2 to 10 years before the final period. During perimenopause, ovarian hormone production becomes erratic: oestrogen fluctuates widely rather than declining linearly, FSH rises progressively as the ovaries become less responsive, and the menstrual cycle becomes irregular. Many women experience their most disruptive symptoms during perimenopause, not after menopause — yet this phase is frequently unrecognised and untreated.

Symptoms of Perimenopause and Menopause

Vasomotor Symptoms

Hot flushes (sudden episodes of intense heat, flushing, and sweating, often followed by chills) and night sweats are the most widely recognised menopausal symptoms, affecting 60 to 80% of women to some degree. Severe symptoms affect approximately 10 to 20% — significantly disrupting sleep, concentration, and daily function. Vasomotor symptoms typically begin in perimenopause, peak in the 2 years around the final period, and gradually diminish over the following 3 to 5 years — though they persist beyond 7 years in approximately 10% of women.

Sleep Disturbance

Frequently driven by night sweats but also occurs independently of vasomotor symptoms. Chronic sleep disruption has cascading effects on mood, cognitive function, energy, and metabolic health.

Mood Changes

Irritability, anxiety, and low mood are significantly more common in perimenopause than in premenopause or postmenopause. Partly driven by hormonal fluctuation (oestrogen has direct effects on serotonin and GABA neurotransmitter systems), partly driven by sleep disruption, and partly by the psychological adjustment to a significant life transition. Women with a prior history of depression are at elevated risk of depressive episodes during perimenopause.

Cognitive Changes

"Brain fog" — difficulty concentrating, word-finding difficulties, short-term memory complaints — is reported by approximately 60% of perimenopausal women. Evidence suggests these are real, measurable changes during the hormonal transition, not imagined, and typically improve after menopause is established.

Genitourinary Syndrome of Menopause (GSM)

Oestrogen deficiency causes progressive atrophy of the vaginal and urethral tissues — thinning, dryness, loss of elasticity, and a shift toward a more alkaline vaginal environment. GSM affects approximately 50% of postmenopausal women and causes:

• Vaginal dryness and discomfort during intercourse (dyspareunia)
• Urinary urgency and frequency
• Recurrent urinary tract infections
• Urinary stress incontinence

Unlike vasomotor symptoms, GSM does not improve over time without treatment — it is a progressive condition that worsens with advancing age. It is also the most undertreated menopausal symptom in India, where many women do not report it due to embarrassment.

Long-Term Health Consequences of Oestrogen Deficiency

Bone Health

Oestrogen directly protects bone density by inhibiting osteoclast activity. After menopause, bone loss accelerates sharply — 1 to 3% per year in the first 5 years of menopause, compared to approximately 0.5% per year before menopause. By the time of the average Indian woman's death, a significant proportion will have had at least one osteoporotic fracture. Hip fractures in elderly women carry 20 to 30% mortality in the year following the fracture.

Bone density assessment (DEXA scan) is appropriate at the time of menopause or within 5 years of the final period. Calcium and vitamin D supplementation are the foundation of bone protection; hormone therapy is the most potent pharmacological bone protection available.

Cardiovascular Risk

Oestrogen protects cardiovascular health — raising HDL cholesterol, protecting arterial endothelium, and reducing arterial stiffness. After menopause, this protection is lost. By the early sixties, women's cardiovascular risk approaches that of men of the same age. Indian women — with high background rates of insulin resistance, dyslipidaemia, and hypertension — are particularly vulnerable.

Treatment: Menopausal Hormone Therapy (MHT)

MHT — replacing the oestrogen (and, in women with a uterus, progesterone) that the ovaries are no longer producing — remains the most effective treatment for menopausal symptoms and has significant protective effects on bone and cardiovascular health when started within 10 years of menopause or before age 60.

The 2002 Women's Health Initiative (WHI) study generated widespread fear about MHT, particularly breast cancer risk. Subsequent re-analysis and newer data have substantially revised this picture:

• The absolute breast cancer risk from combined oestrogen-progestogen MHT is small — approximately 1 extra case per 1,000 women per year of use. This is comparable to the risk from drinking 2 units of alcohol per day or being overweight.
• Oestrogen-only MHT (for women who have had a hysterectomy) does not increase breast cancer risk in most analyses.
• The cardiovascular and mortality benefits of MHT started within 10 years of menopause ("the timing hypothesis") are substantial — and are not seen in women starting MHT more than 10 years after menopause.

Current guidance from NICE (UK), NAMS (USA), and IMS (International Menopause Society) is clear: for healthy women under 60, within 10 years of menopause, without specific contraindications, the benefits of MHT substantially outweigh the risks.

Non-Hormonal Treatment Options

For women who cannot or prefer not to use MHT:

• SSRI/SNRI antidepressants: Paroxetine, venlafaxine, and escitalopram are effective for vasomotor symptoms — 50 to 60% reduction in hot flush frequency compared to placebo.
• Gabapentin: Effective for vasomotor symptoms, particularly night sweats.
• Fezolinetant (an NK3 receptor antagonist): A newer non-hormonal specifically designed for vasomotor symptoms — reduces hot flush frequency by 50 to 70% without hormonal effects.
• Local vaginal oestrogen: For GSM specifically — very low systemic absorption, safe even in women with breast cancer history. Available as creams, pessaries, or rings.

Frequently Asked Questions

Q1. I am 44 and my periods have become irregular. Am I in menopause?

Probably perimenopause — not yet menopause. Perimenopause begins years before the final period, with irregular cycles and fluctuating symptoms. Menopause is only confirmed after 12 consecutive months without a period. An FSH and oestradiol measurement can help characterise where you are in the transition. Importantly, fertility — though declining — is not zero in perimenopause; contraception remains advisable if pregnancy is not desired.

Q2. Is HRT safe for Indian women?

Yes, for most healthy Indian women under 60 who have recently entered menopause, MHT offers more benefit than risk. Individual factors — personal history of breast cancer, cardiovascular disease, thrombosis, liver disease — must be assessed. A specialist menopause consultation provides the personalised risk-benefit discussion that a general practitioner visit often does not have time for.

Q3. Will menopause cause weight gain?

Menopause is associated with a shift in fat distribution toward the abdomen — even without significant overall weight gain. This is partly driven by oestrogen withdrawal and partly by age-related metabolic slowdown. MHT does not cause weight gain — in some studies, it modestly reduces the tendency toward central adiposity. Regular resistance exercise and dietary quality are the most effective countermeasures to menopausal metabolic changes.